Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682509 · ClinicalTrials.gov registry record · Early Phase 1
A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation
A Early Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04682509 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT04682509, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV.
Interventions
- DRUG Glecaprevir/pibrentasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-20 |
| Est. Completion | 2024-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682509
The ClinicalTrials.gov registry entry for NCT04682509 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir/pibrentasvir is the first listed.
NCT04682509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04682509 about?
NCT04682509 is a clinical study titled "A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation". The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV.
What is the current status of trial NCT04682509?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2022-03-20. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT04682509?
The interventions under investigation include: Glecaprevir/pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT04682509?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.